Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0269881117693736 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation.
Schizophr Bull
December 2024
School of Medicine, University College Dublin, Dublin, D04 V1W8, Ireland.
Background: Overweight and obesity are highly prevalent in people with severe mental illness (SMI). Antipsychotic-induced weight gain (AIWG) is one of the most commonly reported and distressing side effects of treatment and people living with SMI place a high value on the avoidance of this side effect. Metformin is the most effective pharmacological intervention studied for the prevention of AIWG yet clear guidelines are lacking and evidence has not translated into practice.
View Article and Find Full Text PDFManagement of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study.
BMC Psychiatry
November 2024
Department of Psychiatry & Neuropsychology, Maastricht University, PO Box 616, Maastricht, 6200, MD, The Netherlands.
Article Synopsis
- - Antipsychotic-induced weight gain (AIWG) is a major issue, and this study explores the effectiveness of oral semaglutide, a GLP-1 agonist, in promoting weight loss among patients experiencing AIWG.
- - In a cohort study over 16 weeks, patients on semaglutide lost an average of 4.5 kg, compared to 2.9 kg in those taking metformin, with both treatments showing improvements in body mass index (BMI) and waist circumference.
- - Both treatments had mild side effects, primarily nausea, with semaglutide notably improving patients' psychiatric symptoms and overall quality of life, suggesting it as a safe and effective option for managing AIWG.
Metformin in the management of antipsychotic-induced weight gain - why the 'weight'?
Front Psychiatry
November 2024
Pharmaceutical Care Research Group, School of Pharmacy, University College Cork, Cork, Ireland.
The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis.
Schizophr Bull
November 2024
School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan.
Background: Weight gain and metabolic complications are substantial adverse effects associated with second-generation antipsychotics. However, comprehensive guidelines for managing antipsychotic-induced weight gain are lacking.
Methods: This review included all double-blind, placebo-controlled studies investigating metformin's effectiveness in addressing antipsychotic-related weight gain.
Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: A network meta-analysis.
Gen Hosp Psychiatry
September 2024
Additional Professor, Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar. Electronic address:
Objective: Antipsychotic-induced weight gain (AIWG) is a significant but frequently neglected adverse effect of first- and second-generation antipsychotic therapy, which may lead to cardiovascular disturbances. The present network meta-analysis (NMA) was conducted to evaluate and compare the effects of available treatment options in antipsychotic-induced weight gain (AIWG).
Methods: The data was extracted from 68 relevant clinical trials after a literature search on MEDLINE/PubMed, Embase, Scopus, Cochrane databases and clinical trial registries.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!